189 related articles for article (PubMed ID: 18640168)
1. Immunogenicity of a recombinant envelope domain III protein of dengue virus type-4 with various adjuvants in mice.
Babu JP; Pattnaik P; Gupta N; Shrivastava A; Khan M; Rao PV
Vaccine; 2008 Aug; 26(36):4655-63. PubMed ID: 18640168
[TBL] [Abstract][Full Text] [Related]
2. Pichia pastoris-expressed dengue virus type 2 envelope domain III elicits virus-neutralizing antibodies.
Batra G; Raut R; Dahiya S; Kamran N; Swaminathan S; Khanna N
J Virol Methods; 2010 Jul; 167(1):10-6. PubMed ID: 20211204
[TBL] [Abstract][Full Text] [Related]
3. Expression, purification and evaluation of diagnostic potential and immunogenicity of dengue virus type 3 domain III protein.
Reddy PB; Pattnaik P; Tripathi NK; Srivastava A; Rao PV
Protein Pept Lett; 2012 May; 19(5):509-19. PubMed ID: 22486646
[TBL] [Abstract][Full Text] [Related]
4. A vaccine formulation consisting of nucleocapsid-like particles from Dengue-2 and the fusion protein P64k-domain III from Dengue-1 induces a protective immune response against the homologous serotypes in mice.
Lazo L; Gil L; López C; Valdés I; Blanco A; Pavón A; Romero Y; Guzmán MG; Guillén G; Hermida L
Acta Trop; 2012 Nov; 124(2):107-12. PubMed ID: 22750482
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of recombinant E2 protein-based and whole-virus inactivated candidate vaccines against chikungunya virus.
Kumar M; Sudeep AB; Arankalle VA
Vaccine; 2012 Sep; 30(43):6142-9. PubMed ID: 22884660
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of immune responses elicited in mice against a recombinant malaria vaccine based on Plasmodium vivax Duffy binding protein.
Yazdani SS; Shakri AR; Mukherjee P; Baniwal SK; Chitnis CE
Vaccine; 2004 Sep; 22(27-28):3727-37. PubMed ID: 15315853
[TBL] [Abstract][Full Text] [Related]
7. Tetravalent dengue DIIIC protein together with alum and ODN elicits a Th1 response and neutralizing antibodies in mice.
Zuest R; Valdes I; Skibinski D; Lin Y; Toh YX; Chan K; Hermida L; Connolly J; Guillen G; Fink K
Vaccine; 2015 Mar; 33(12):1474-82. PubMed ID: 25659270
[TBL] [Abstract][Full Text] [Related]
8. High-level expression of recombinant dengue virus type 2 envelope domain III protein and induction of neutralizing antibodies in BALB/C mice.
Zhang ZS; Yan YS; Weng YW; Huang HL; Li SQ; He S; Zhang JM
J Virol Methods; 2007 Aug; 143(2):125-31. PubMed ID: 17532481
[TBL] [Abstract][Full Text] [Related]
9. Serotype specificity of recombinant fusion protein containing domain III and capsid protein of dengue virus 2.
Izquierdo A; Valdés I; Gil L; Hermida L; Gutiérrez S; García A; Bernardo L; Pavón A; Guillén G; Guzmán MG
Antiviral Res; 2012 Jul; 95(1):1-8. PubMed ID: 22554934
[TBL] [Abstract][Full Text] [Related]
10. Bacterially expressed recombinant envelope protein domain III of Japanese encephalitis virus (rJEV-DIII) elicits Th1 type of immune response in BALB/c mice.
Verma SK; Kumar S; Gupta N; Vedi S; Bhattacharya SM; Lakshmana Rao PV
Vaccine; 2009 Nov; 27(49):6905-9. PubMed ID: 19761840
[TBL] [Abstract][Full Text] [Related]
11. Recombinant lipidated dengue-3 envelope protein domain III stimulates broad immune responses in mice.
Chiang CY; Liu SJ; Hsieh CH; Chen MY; Tsai JP; Liu HH; Chen IH; Chong P; Leng CH; Chen HW
Vaccine; 2016 Feb; 34(8):1054-61. PubMed ID: 26776472
[TBL] [Abstract][Full Text] [Related]
12. Preparation and immunogenic properties of a recombinant West Nile subunit vaccine.
Lieberman MM; Clements DE; Ogata S; Wang G; Corpuz G; Wong T; Martyak T; Gilson L; Coller BA; Leung J; Watts DM; Tesh RB; Siirin M; Travassos da Rosa A; Humphreys T; Weeks-Levy C
Vaccine; 2007 Jan; 25(3):414-23. PubMed ID: 16996661
[TBL] [Abstract][Full Text] [Related]
13. A novel dengue vaccine candidate that induces cross-neutralizing antibodies and memory immunity.
Leng CH; Liu SJ; Tsai JP; Li YS; Chen MY; Liu HH; Lien SP; Yueh A; Hsiao KN; Lai LW; Liu FC; Chong P; Chen HW
Microbes Infect; 2009 Feb; 11(2):288-95. PubMed ID: 19114121
[TBL] [Abstract][Full Text] [Related]
14. Virus-like particles displaying envelope domain III of dengue virus type 2 induce virus-specific antibody response in mice.
Arora U; Tyagi P; Swaminathan S; Khanna N
Vaccine; 2013 Jan; 31(6):873-8. PubMed ID: 23261049
[TBL] [Abstract][Full Text] [Related]
15. Tests in mice of a dengue vaccine candidate made of chimeric Junin virus-like particles and conserved dengue virus envelope sequences.
Mareze VA; Borio CS; Bilen MF; Fleith R; Mirazo S; Mansur DS; Arbiza J; Lozano ME; Bruña-Romero O
Appl Microbiol Biotechnol; 2016 Jan; 100(1):125-33. PubMed ID: 26386688
[TBL] [Abstract][Full Text] [Related]
16. Protective immunity to DENV2 after immunization with a recombinant NS1 protein using a genetically detoxified heat-labile toxin as an adjuvant.
Amorim JH; Diniz MO; Cariri FA; Rodrigues JF; Bizerra RS; Gonçalves AJ; de Barcelos Alves AM; de Souza Ferreira LC
Vaccine; 2012 Jan; 30(5):837-45. PubMed ID: 22178517
[TBL] [Abstract][Full Text] [Related]
17. Targeting of envelope domain III protein of DENV type 2 to DEC-205 receptor elicits neutralizing antibodies in mice.
Coconi-Linares N; Ortega-Dávila E; López-González M; García-Machorro J; García-Cordero J; Steinman RM; Cedillo-Barrón L; Gómez-Lim MA
Vaccine; 2013 May; 31(19):2366-71. PubMed ID: 23499580
[TBL] [Abstract][Full Text] [Related]
18. CpG oligodeoxynucleotide and montanide ISA 206 adjuvant combination augments the immune responses of a recombinant FMDV vaccine in cattle.
Ren J; Yang L; Xu H; Zhang Y; Wan M; Liu G; Zhao L; Wang L; Yu Y
Vaccine; 2011 Oct; 29(45):7960-5. PubMed ID: 21872635
[TBL] [Abstract][Full Text] [Related]
19. Induction of neutralizing antibodies and T cell responses by dengue virus type 2 envelope domain III encoded by plasmid and adenoviral vectors.
Khanam S; Khanna N; Swaminathan S
Vaccine; 2006 Oct; 24(42-43):6513-25. PubMed ID: 16860446
[TBL] [Abstract][Full Text] [Related]
20. DENV-2 subunit proteins fused to CR2 receptor-binding domain (P28)-induces specific and neutralizing antibodies to the Dengue virus in mice.
García-Machorro J; López-González M; Barrios-Rojas O; Fernández-Pomares C; Sandoval-Montes C; Santos-Argumedo L; Villegas-Sepúlveda N; Gutiérrez-Castañeda B; Cedillo-Barrón L
Hum Vaccin Immunother; 2013 Nov; 9(11):2326-35. PubMed ID: 23880886
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
